ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,582,268 | +13.0% | 3,732,606 | +44.9% | 0.00% | 0.0% |
| Q2 2023 | $19,984,181 | +407.7% | 2,575,281 | +273.0% | 0.00% | – |
| Q1 2023 | $3,935,930 | -16.3% | 690,514 | -13.5% | 0.00% | – |
| Q4 2022 | $4,702,505 | +41.5% | 798,388 | -23.2% | 0.00% | – |
| Q3 2022 | $3,324,000 | -7.2% | 1,038,942 | +30.0% | 0.00% | – |
| Q2 2022 | $3,581,000 | -71.7% | 799,341 | -66.3% | 0.00% | – |
| Q1 2022 | $12,676,000 | -64.3% | 2,373,900 | -1.7% | 0.00% | -100.0% |
| Q4 2021 | $35,504,000 | -29.6% | 2,415,347 | +0.2% | 0.00% | 0.0% |
| Q3 2021 | $50,406,000 | +25.5% | 2,410,542 | +6.2% | 0.00% | 0.0% |
| Q2 2021 | $40,162,000 | -14.2% | 2,270,310 | +18.8% | 0.00% | 0.0% |
| Q1 2021 | $46,802,000 | -26.4% | 1,910,353 | +1.7% | 0.00% | -50.0% |
| Q4 2020 | $63,602,000 | +228.5% | 1,878,908 | +142.7% | 0.00% | +100.0% |
| Q3 2020 | $19,363,000 | -33.9% | 774,207 | -10.9% | 0.00% | 0.0% |
| Q2 2020 | $29,309,000 | – | 868,941 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |